Long-term effect of antiviral therapy for grade II cervical intraepithelial neoplasia

BACKGROUND: The production of many molecular markers at different grades of cervical intraepithelial neoplasia is currently being studied to predict the outcome of the disease and build an individual prognosis. However, no clear criteria for the course of neoplasia are available at this time. AIM: This study aimed to assess the efficiency of the antiviral immunomodulator Allokin-alpha (Alloferon) in the treatment of cervical intraepithelial neoplasia of moderate severity from the perspective of long-term follow-up. DESIGN: Prospective study. MATERIALS AND METHODS: We examined 86 women of reproductive age with grade II cervical intraepithelial neoplasia (CIN II) associated with human papillomavirus (HPV). In the CIN II group, all patients underwent excision of the affected area. According to the study design, 43 women were followed up after excision (Group 1a), while 43 participants were treated surgically and used the study drug (Group 1b). By cytological and colposcopic examination, the efficiency of the chosen therapy was assessed after 3, 12, and 18 months. However, the main criteria for the efficiency of treatment were the absence of HPV or a decrease in the viral load below significant values and the absence of recurrence of the pathological process. RESULTS: The combination of excision and the use of Allokin-alpha (Alloferon) showed significant advantages over monosurgical treatment. CONCLUSIONS: The data obtained indicate high HPV elimination and reduced probability of recurrence after excisional treatment in patients with CIN II when using Allokin-alpha (Alloferon).